Please login to the form below

Not currently logged in
Email:
Password:

Valeant

This page shows the latest Valeant news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Andrew Witty's replacement on Accelerated Access initiative, Blincyto gains full EU approval and more

Daily Brief: Andrew Witty's replacement on Accelerated Access initiative, Blincyto gains full EU approval and more

Valeant shares tumble after FDA rejection. A rejection by the US regulator for Valeant’s plaque psoriasis treatment. ... Valeant said in a statement that the FDA had not specified any clinical efficacy or safety shortcomings in its Complete Response

Latest news

More from news
Approximately 47 fully matching, plus 112 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    $35bn. $7.3bn. Valeant. 40. 17.5. -56%. $28bn. ($2.4bn). Perrigo. 90. 78. ... Perrigo, like Teva and Valeant, is seeking to reduce debt. Biotech companies are also selling (or licensing) assets to stay alive.

  • Deal Watch - May 2017 Deal Watch - May 2017

    It is likely that in the next few months companies such as Teva and Valeant that are having a difficult time at the moment will divest parts of their business.

  • Deal Watch March 2017 Deal Watch March 2017

    There are more below the radar (without accompanying numbers), for example: Valeant has granted Glycyx a sublicence to develop products containing methylnaltrexone bromide for oncology indications, and Fuji Pharma has obtained

  • Deal Watch January 2017 Deal Watch January 2017

    Bringing in an additional $819.9m in cash, Valeant also sold its equity interest in Dendreon (manufacturer of Provenge, a personalised immunotherapy) to the Sanpower Group. ... 1, 600. Valeant. L'Oreal. Divestment. CeraVe AcneFree AMBI. 1, 300. Forward

  • Deal Watch August 2016 Deal Watch August 2016

    Finally it was interesting to see that Pharming has recovered from Valeant the North American rights to its product Ruconest. ... Pharming did well to get the rights back especially as it resulted in Valeant having to make a $199m write down of its

More from intelligence
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest appointments

  • ThermiGen appoints Vladimir Paul-Blanc as president ThermiGen appoints Vladimir Paul-Blanc as president

    He previously served Solta Medical - the aesthetics energy device division of Valeant Pharmaceuticals – as its general manager.

  • BMS appoints three independent directors BMS appoints three independent directors

    Robert Bertolini brings strategic and operational leadership experience from Bausch &Lomb, where he recently served as president and chief financial officer prior to the company's sale to Valeant.

  • Valeant appoints Joseph Papa to end CEO uncertainty Valeant appoints Joseph Papa to end CEO uncertainty

    Valeant appoints Joseph Papa to end CEO uncertainty. He will take over from Michael Pearson at the troubled pharma company in May. ... Searle &Company, Novartis and Pharmacia Corporation. He said: “ I am excited to take on the challenge of leading

  • Valeant adds member to board of directors Valeant adds member to board of directors

    Morfit had originally served on Valeant's board of directors between 2007 and 2014. ... Michael Pearson, chairman and CEO of Valeant, said: “ I am pleased to welcome Mason back to the Valeant board of directors. “

  • Valeant adds Robert Hale to board of directors Valeant adds Robert Hale to board of directors

    Valeant adds Robert Hale to board of directors. And Jeffrey Ubben resigns from the board. ... He said: “ I have had a wonderful experience serving as director of Valeant.

More from appointments
Approximately 6 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics